Press Releases
February 9, 2010 — FlowCardia, Inc. Initiates CENTRAL Study Enrollment
January 8, 2010 — Mark Page appointed Vice President Marketing for FlowCardia, Inc
October 21, 2009 — FlowCardia, Inc. expands treatment options for patients with chronic total occlusions
October 6, 2009 — FlowCardia, Inc. Launches FlowMate™ Injector to Optimize Performance of CROSSER® CTO Recanalization Catheter
July 23, 2009 — FlowCardia Appoints Chris Barys to Chief Operating Officer
June 18, 2008 — FlowCardia, Inc. Appoints Deborah DeFilippo CFO
December 11, 2007 — FlowCardia, Inc. Launches Peripheral CROSSER Catheter Portfolio in the US — A New, Endovascular Option to Amputation and Bypass Surgery
December 5, 2007 — FlowCardia, Inc. Appoints Chris Barys Senior VP, Sales
September 5, 2007 — FlowCardia, Inc. Announces Final Enrollment in the PATRIOT Peripheral Study with the CROSSER™ Family of CTO Recanalization Catheters
August 30, 2007 — FlowCardia, Inc. Raises $30 Million in Series C Financing
January 25, 2007 — FlowCardia, Inc. Announces Availability of the Peripheral CROSSER™ Catheter Portfolio in Europe — A New, Endovascular Option to Amputation and Bypass Surgery
January 23, 2007 — FlowCardia, Inc. Announces 510(k) Clearance for the CROSSER™ 14 Chronic Total Occlusion Recanalization System — A New, Minimally Invasive Option to Bypass Surgery
November 2, 2006 — FlowCardia, Inc. Initiates PATRIOT Pivotal Study Enrollment and Announces Coronary FDA 510(k) Submission for CROSSER™ Catheter System
September 21, 2006 — A World First in Pediatric Cardiology: The Montreal Heart Institute and the Sainte-Justine UHC Have Achieved a World First in the Treatment of a Young Patient with a Completely Blocked Yet Vital Heart Artery (Montreal Press Conference Video)
August 8, 2006 — FlowCardia, Inc. Completes Enrollment in FACTOR Coronary Pivotal Study and Initiates PATRIOT Peripheral Pivotal Study with the CROSSER™ CTO Recanalization System
Jun 21, 2006 — FlowCardia, Inc. Completes Enrollment in PATRIOT Peripheral Feasibility Study with the CROSSER CTO Recanalization System
Jan 04, 2006 — FlowCardia, Inc. Introduces First Products to Market and Delivers Clinical Update on FACTOR U.S. Pivotal Trial
Jan 28, 2005 — FlowCardia, Inc. Receives European Regulatory Approval and Successfully Completes U.S. Feasibility Clinical Trial
Jan 27, 2005 — FlowCardia, Inc. Appoints Mark Stautberg to Board of Directors
|
